Immunomedics, Inc., IMMU
today announced that isactuzumab govitecan (IMMU-132), the Company's
proprietary solid-tumor antibody-drug conjugate (ADC), continues to produce
encouraging results in a Phase 2 clinical trial in heavily-pretreated patients
with diverse, metastatic solid cancers. The provisional results were presented
by Dr. David M. Goldenberg, Chairman, Chief Scientific Officer, and Chief
Medical Officer, at the 5th Annual World ADC Summit in San Diego, CA.
In 113 patients who have received at least one dose of isactuzumab govitecan,
treatments with the ADC resulted in at least 64 patients (57%) with partial
responses and disease stabilization. All lesions were measured by computed
tomography (CT) based on RECIST 1.1 criteria. The major responses were
observed among patients with 6 different advanced cancers, including
triple-negative breast, small-cell and non-small-cell lung, colorectal,
esophageal, and urinary bladder cancers.
The ADC was well tolerated at the Phase 2 dose used in the trial expansion,
with neutropenia being the major toxicity, and about 10% of patients having
grade 3 and 4 other toxicities. This suggests a higher therapeutic index
(ratio of therapeutic benefit to toxicity) than historical results with
irinotecan, SN-38's parent compound.
"We are most encouraged with the results in patients with triple-negative
breast cancer, small-cell and non-small-cell lung cancers, especially in these
patients who have late-stage diseases," remarked Cynthia L. Sullivan,
President and Chief Executive Officer. "We plan to complete the Phase 2 study
before the end of this year. Discussions with key opinion leaders, as well as
potential corporate partners, on the further development of this valuable
agent are ongoing," Ms. Sullivan added.
Isactuzumab govitecan is made up of SN-38, the active metabolite of
irinotecan, conjugated to the Company's humanized anti-TROP-2 antibody. TROP-2
is expressed by many human tumors, such as cancers of the breast, cervix,
colon and rectum, kidney, liver, lung, ovary, pancreas, and prostate, but with
only limited expression in normal human tissues. Preclinical studies have
indicated that isactuzumab govitecan delivers up to 135-times the amount of
SN-38 to a human pancreatic tumor xenograft than when irinotecan is given. In
patients who relapsed or were refractive to prior topoisomerase I or II
inhibitors, this ADC demonstrated subsequent activity, suggesting that it can
overcome resistance to such inhibitors, including irinotecan.
In addition to isactuzumab govitecan (IMMU-132), the Company is also
developing another SN-38 based ADC, labetuzumab govitecan (IMMU-130), for the
treatment of patients with metastatic colorectal cancer. The clinical study of
this agent is advancing into a Phase 2 trial, with some patients under therapy
for many months and showing long-term disease control after failing prior
irinotecan-containing regimens. Here again, despite the frequent dosing, the
ADC appears to be well tolerated by patients, with transient and reversible
neutropenia, and manageable diarrhea the major side effects, which were mild
and irregular.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in